SPYRE THERAPEUTICS, INC. Net Cash Provided by (Used in) Financing Activities, Continuing Operations
SPYRE THERAPEUTICS, INC. (SYRE) reported Net Cash Provided by (Used in) Financing Activities, Continuing Operations of $38.75 million for the 6-month period ending 2018-06-30, per its 10-Q filed 2018-08-09.
Discontinued › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations · last filed 2018-08-09
- SPYRE THERAPEUTICS, INC. net cash provided by (used in) financing activities, continuing operations for the quarter ending 2018-06-30 was $38.06M, a 229.52% increase year-over-year.
- SPYRE THERAPEUTICS, INC. net cash provided by (used in) financing activities, continuing operations for the quarter ending 2018-03-31 was $688.00K, a 616.67% increase year-over-year.
- SPYRE THERAPEUTICS, INC. net cash provided by (used in) financing activities, continuing operations for the quarter ending 2017-12-31 was $684.00K.
- SPYRE THERAPEUTICS, INC. net cash provided by (used in) financing activities, continuing operations for the quarter ending 2017-09-30 was -$118.00K, a 255.26% decline year-over-year.
- SPYRE THERAPEUTICS, INC. net cash provided by (used in) financing activities, continuing operations for fiscal 2017 was $12.21M, a 75.26% decline from fiscal 2016.
- SPYRE THERAPEUTICS, INC. net cash provided by (used in) financing activities, continuing operations for fiscal 2016 was $49.37M, a 18.47% increase from fiscal 2015.
- SPYRE THERAPEUTICS, INC. net cash provided by (used in) financing activities, continuing operations for fiscal 2015 was $41.67M, a 647.52% increase from fiscal 2014.
- SPYRE THERAPEUTICS, INC. net cash provided by (used in) financing activities, continuing operations for fiscal 2014 was $5.58M.
| Period end | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2018-06-30 | $38.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $38.75M 10-Q · filed 2018-08-09 | $39.44M derived: sum of 3 quarters · filed 2018-08-09 | $39.32M derived: sum of 4 quarters · filed 2018-08-09 |
| 2018-03-31 | $688.00K 10-Q · filed 2018-05-08 | $1.37M derived: sum of 2 quarters · filed 2018-05-08 | $1.25M derived: sum of 3 quarters · filed 2018-05-08 | $12.80M derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-12-31 | $684.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | $566.00K derived: sum of 2 quarters · filed 2018-03-13 | $12.12M derived: sum of 3 quarters · filed 2018-08-09 | $12.21M 10-K · filed 2018-03-13 |
| 2017-09-30 | -$118.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $11.43M derived: sum of 2 quarters · filed 2018-08-09 | $11.53M 10-Q · filed 2017-11-07 | $11.53M derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-06-30 | $11.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $11.65M 10-Q · filed 2018-08-09 | $11.65M derived: sum of 3 quarters · filed 2018-08-09 | $11.72M derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-03-31 | $96.00K 10-Q · filed 2018-05-08 | $96.00K derived: sum of 2 quarters · filed 2018-05-08 | $172.00K derived: sum of 3 quarters · filed 2018-05-08 | $49.56M derived: sum of 4 quarters · filed 2018-05-08 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | $76.00K derived: sum of 2 quarters · filed 2018-03-13 | $49.47M derived: sum of 3 quarters · filed 2018-03-13 | $49.37M 10-K · filed 2018-03-13 |
| 2016-09-30 | $76.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $49.47M derived: sum of 2 quarters · filed 2017-11-07 | $49.37M 10-Q · filed 2017-11-07 | $49.17M derived: sum of 4 quarters · filed 2018-03-13 |
| 2016-06-30 | $49.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $49.29M 10-Q · filed 2017-08-09 | $49.09M derived: sum of 3 quarters · filed 2018-03-13 | $48.12M derived: sum of 4 quarters · filed 2018-03-13 |
| 2016-03-31 | -$98.00K 10-Q · filed 2017-05-09 | -$301.00K derived: sum of 2 quarters · filed 2018-03-13 | -$1.27M derived: sum of 3 quarters · filed 2018-03-13 | -$2.10M derived: sum of 4 quarters · filed 2018-03-13 |
| 2015-12-31 | -$203.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | -$1.17M derived: sum of 2 quarters · filed 2018-03-13 | -$2.00M derived: sum of 3 quarters · filed 2018-03-13 | $41.67M 10-K · filed 2018-03-13 |
| 2015-09-30 | -$970.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$1.80M derived: sum of 2 quarters · filed 2016-11-09 | $41.88M 10-Q · filed 2016-11-09 | |
| 2015-06-30 | -$831.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $42.85M 10-Q · filed 2016-08-09 | ||
| 2015-03-31 | $43.68M 10-Q · filed 2016-05-19 | |||
| 2014-12-31 | $5.58M 10-K · filed 2017-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |